Secondary hyperparathyreoidism in chronic kidney disease. Role of fibroblast growth factor-23 (FGF-23) and Klotho


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Проанализированы современные представления о развитии и прогрессировании вторичного гиперпаратиреоза, основанные на новых данных о патофизиологии и молекулярных механизмах взаимодействия фосфат- регулирующих систем - паратиреоидного гормона, FGF-23/Klotho и кальцитриола.

Full Text

Restricted Access

References

  1. Gutiérrez O.M., Mannstadt M., Isakova T. et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. New Engl. J. Med. 2008;359:584—592.
  2. Makoto K. Klotho in chronic kidney disease — What's new? N.D.T. 2009;24(6):1705—1708.
  3. Милованова Л.Ю., Козловская Л.В., Милованов Ю. С. и др. Механизмы нарушения фосфорно-кальциевого гомеостаза в развитии сердечнососудистых осложнений у больных хронической болезнью почек. Роль фактора роста фибробластов-23 (FGF-23) и Klotho. Тер. арх. 2010;6:66—72.
  4. Milovanova L., Milovanov Y., Kozlovskay L. The clinical significance of morphogenetic protein-FGF-23 and Klotho serum determining in Chronic Kidney Disease patients Tesis of ERA-EDTA Conference. 2012; May. Paris.
  5. Quarles L.D. Endocrine function of bone in mineral metabolism. Clin. J. Invest. 2008;118(12):3820—3828.
  6. Milovanova L., Milovanov Y., Plotnikova A. Phosphorus and Calcium Metabolism Disorders Assosiated with Chronic Kidney Disease Stage III—IV (Systematic Rewiew and Meta-Analysis). Chronic Kidney Disease and renal Transplantation. Ed. by Manisha Sahay. INTECH. 2012;95—118.
  7. Kendrick J., Cheung A. K, Kaufman J. S. et al. FGF-23 Associates with Death, Cardiovascular Events, and Initiation of Chronic Dialysis. Am. J. Soc. Nephrol. 2011; 22(10): 1913—1922.
  8. Gutierrez O., Isakova T., Rhee E. et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. Am. J. Soc. Nephrol. 2005; 16: 2205—2215.
  9. Isakova T., Walh P., Vargas G.S. et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011; 79(12): 1370—1378.
  10. Chung-Yi C., Makoto K., Mohammed S. Razzaque Molecular Regulation of Phosphate Metabolism by Fibroblast Growth Factor-23—Klotho System: Adv Chronic Kidney Dis. 2011;18(2): 91—97.
  11. Hu M.C., Shi M., Zhang J. et al. Klotho deficiency causes vascular calcification in chronic kidney disease. Am. J. Soc. Nephrol. 2011; 22: 124—136.
  12. Hu M.C., Shi M., Zhang. J. et al. Klotho deficiency is an early biomarker of renal ischemia—reperfusion injury and its replacement is protective. Kidney Int. 2010;78(12): 1240—1251.
  13. Liu S., Quarles L.D. How fibroblast growth factor 23 works. Am. J. Soc. Nephrol. 2007; 18(6):1637—1647.
  14. Prie D., Torres P.U., Friedlander G. Latest findings in phosphate homeostasis. Kidney Int. 2009;75 (9): 882—889.
  15. Wolf M. Forgingforward with 10 burning questions on FGF23 in kidney disease. Am. J. Soc. Nephrol. 2010; 21 (9):1427—1435.
  16. Arcidiacono M.V., Cozzolino M., Spiegel N. et al. Activator Protein 2a Mediates Parathyroid TGF-a Self-Induction in Secondary Hyperparathyroidism. Am. J. Soc. Nephrol. 2008;19(10):1919—1928.
  17. Dusso A.S., Pavlopoulos T., Naumovich L. et al. p21 WAF1 and transforming growth factor-β mediate dietary phosphate regulation of parathyroid cell growth. Kidn. Int. 2001;59(3):855—865.
  18. Wells A. EGF receptor. Int. J. Biochem. Cell. Biol. 1999; 31: 637—643.
  19. Chen C.D., Podvin S., Gillespie E. et al. Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM 10 and ADAM 17. Proc. Natl. Acad Sci USA 2007;104(50): 19796—9801.
  20. Hu M.C., Shi M., Zhang J. et al. Klotho deficiency causes vascular calcification in chronic kidney disease. Am. J. Soc. Nephrol. 2011; 22(1): 124—36.
  21. Bloch L., Sineshchekova O., Reichenbach D. et al. Klotho is a substrate for a-, β- and г-secretase. FEBS Lett. 2009; 583(19): 3221—3224.
  22. Cordero J.B., Cozzolino M., Lu Y. et al. 1,25-Dihydroxyvitamin D down-regulates cell membrane growth-and nuclear growth-promoting signals by the epidermal growth factor receptor. Biol. J. Chem. 2002;277(41):38965—38971.
  23. Jiang Y., Wang M. Over expression ofparathyroidpituitary-specific transcription factor (Pit-1) in hyperphosphatemia-induced hyperparathyroidism of chronic renal failure rats. Clin. Med. J. Engl. 2010; 123(12): 1566—1570.
  24. Dusso A. Kidney disease and vitamin D levels: 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and VDR activation. Kidney Int. 2011; (Suppl. 1): 136—141.
  25. Keith A. H., Suresh M. The Roles of the Skeleton and Phosphorus in the CKD Mineral Bone Disorder Adv Chronic Kidney Dis. Adv Chronic Kidney Dis. 2011;18(2):98—104.
  26. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evalution, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).Kidney Int. 2009;76(Suppl. 113): S1—S130.
  27. Национальные рекомендации по минеральным и костным нарушениям при хронической болезни почек. Российское диализное общество (май 2010). Нефрол. и диал. 2011;13(1):33-51.
  28. Милованова Л.Ю., Милованов Ю.С., Козловская Л.В. Нарушения фосфорно-кальциевого обмена при хронической болезни почек III—IV стадий. Клин. Нефрол. 2011;1:58—68.
  29. Kestenbaum B., Sampson J.N., Rudser K.D. et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. Am. J. Soc. Nephrol. 2005;16:520—528.
  30. Malluche H.H., Mawad H., Monier-Faugere M-C. Effects of Treatment of Renal Osteodystrophy on Bone Histology Clin. Am. J. Soc. Nephrol. 2008; (Suppl. 3): S157—S163.
  31. Coladonato J.A. Control of hyperphosphatemia among tafients with ESRD. Am. J. Nephrol. 2005;16(Suppl. 2): S107—114.
  32. Ritz E., Gross M.L. Hyperphosphatemia in renal failure. Blood Purificat. 2005;23:6—9.
  33. St Peter W.L., Liu J., Weinhandl E., Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am. J. Kidn. Dis. 2008; 51: 445—454.
  34. Tonelli M., Muntner P., Manns B.J. Risk of coronary events in people with diabetes: a population-lovel cohort study. Am. J. Kidney Dis. 2007;49:37—45.
  35. Bellasi A., Mandreoli M., Baldrati L. et al. Chronic Kidney Disease Progression and Outcome According to Serum Phosphorus in Mild-to-Moderate Kidney Dysfunction. Am. J. Soc. Nephrol. 2011; 6(4): 883—891.
  36. Chue C.D., Townend J.N. et al. Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB-PHOS randomised controlled trial. 2011; 12: 30. Published online 2011 February 2.
  37. Милованова Л.Ю., Милованов Ю.С., Добросмыслов И.А. и др. Севеламера гидрохлорид — новые перспективы в коррекции гиперфосфатемии у больных хронической болезнью почек III—VD стадий. Клин. нефрол. 2012; 5: 68—94.
  38. Милованов Ю.С., Милованова Л.Ю., Mоисеев С.В. Выбор фосфатсвязывающего препарата для лечения гиперфосфатемии при хронической болезни почек: эффекты на кальцификацию артерий и смертность. Клин. фармакол. 2012; 21(5): 45—52.
  39. Плотникова А.А., Милованова Л.Ю., Милованов Ю.С. Парикальцитол — новые возможности оптимизации нефропротективной стратегии и лечения вторичного гиперпаратиреоза. Клин. нефрол. 2012; 4: 51—55.
  40. Milovanova L.Yu., Milovanov Yu.S., Kozlovskaya L.V. The place of paricalcitol in nephroprotrctive strategy of predialysis chronic kidney disease due to systemic diseases. Arh. Evromed. 2011; 3: 69—78.
  41. Hansen D. A randomized clinical study of alfacalcidol and paricalcitol. Dan Med. J. 2012;59(2):B4400.
  42. Lindberg J., Martin K.J., Gonzales E.A. et al. A long-term, multicenter study of the efficacy and safety of parycalcitol in end-stage renal disease. Clin. Nephrol. 2001; 56: 315—323.
  43. Borst M.H., Vervloet M.G. Cross Talk Between the Renin-Angiotensin-Aldosterone System and Vitamin D-FGF-23-klotho in Chronic Kidney Disease. Am. J. Soc. Nephrol. 2011;22(9):1603—1609.
  44. Scola N., Kreuter A. Calciphylaxis: a severe complication of renal disease. C.M.A.J. 2011;183(16): 1882—1885.
  45. Milovanov Y.S., Milovanova L.Y., Kozlovskaya L.V. Role of Vitamin D Receptor Selective Activator Paricalcitol in Nephroprotective Strategy in Chronic Kidney Disease. Inrern. J. Biomed. 2011; 1(4): 199—203.
  46. Arcidiacono M.V., Sato T., Hernandez D.A. et al. EGFR Activation Increases Parathyroid Hyperplasia and Calcitriol Resistance in Kidney Disease. J. Am. Soc. Nephrol. 2008;19(2):310—320.
  47. Милованова Л.Ю., Милованов Ю.С., Плотникова А.А. и др. Эктопическая минерализация при хронической болезни почек — механизмы, патогенез, современные возможности профилактики и лечения. Современ. мед. наука. 2012; 1: 16—33.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies